A phase Ia study of seven dose levels of LX 2931 in healthy volunteers.

Trial Profile

A phase Ia study of seven dose levels of LX 2931 in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2008

At a glance

  • Drugs LX 2931 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Lexicon Pharmaceuticals
  • Most Recent Events

    • 17 Apr 2008 Positive results have been reported in a Lexicon media release.
    • 16 Nov 2007 New trial record.
    • 12 Nov 2007 IND application submitted to US FDA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top